Abstract
Although 1–4-dihydropyrines (DHP), stable intermediates of the synthesis of pyridine by the Hantzsch reaction, have been produced since the late nineteenth century, their biological activity remained for a long time uninvestigated. In 1949, Phillips at the Wellcome laboratories in the United States synthetized DHPs and tested them for possible analgesic and curare-like effects [1], Although he evaluated derivatives now known to possess potent calcium-antagonistic properties — his compound No. I differed from nifedipine merely by a nonessential shift to meta position of the NO2 substituent — Phillips thought that actions of the compounds in vivo represented no more than “undesirable side effects” [1].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Phillips A (1949) Hantzsch’s pyridine synthesis. J Amer Chem Soc 71:4003–4007
Bossert F, Vater W (1971) Dihydropyridine, eine neue Gruppe stark wirksamer Coronar-therapeutika. Naturwissenschaften 58:578–578
Fleckenstein VA, Kammermeier H, Döring HJ, Freund HJ (1967) Zum Wirkungsmechanismus neurartiger Koronardilatatoren mit gleichzeitig Sauerstoffeinsparenden Myokard-Effekten, Prenylamin und Iproveratril. Z Kreislaufforschung 56:716–744;
Fleckenstein VA, Kammermeier H, Döring HJ, Freund HJ (1967) Zum Wirkungsmechanismus neurartiger Koronardilatatoren mit gleichzeitig Sauerstoffeinsparenden Myokard-Effekten, Prenylamin und Iproveratril. Z Kreislaufforschung 56:839–858
Glossmann H, Striessnig J, Knaus H-G, Müller J, Grassegger A, Höltje H-D, Marrer S, Hymel L, Schindler HG (1989) Structure of calcium channels. NY Acad Sei 560:198–214
Loeb B, Ehrreich SJ, Tedeschi RE (1972) Dihydropyridines with potent hypotensive activity prepared by the Hantzsch reaction. (Letter to the editor) J Pharm Pharmac 24:917–918
Murakami M, Murakami E, Takekoshi N, Tsuchiya M, Kin T, Onoe T, Takeuchi N, Funatsu T, Hara S, Ishise S, Mifune J, Maeda M (1972) Antihypertensive effect of nifedipine, a new coronary dilator. Jpn Heart J 13:128–135
Olivari MT, Bartorelli C, Polese A, Fiorentini C, Moruzzi P, Guazzi M (1979) Treatment of hypertension with nifedipine, a calcium antagonistic agent. Circulation 59:1056–1062
Pedersen OL (1978) Does verapamil have a clinically significant antihypertensive effect? Eur J Clin Pharmacol 13:21–24
Kiowski W, Bolli MD, Erne P, Müller FB, Hulthén UL, Bühler FR (1989) Mechanisms of action and clinical use of calcium antagonists in hypertension. Circulation 80 [Suppl. VI]: IV-136–IV-144
Frishman WH, Garofalo JL, Rothschild A, Rothschild M, Greenberg SM, Soberman J (1989) The nifedipine gastrointestinal therapeutic system in the treatment of hypertension. Am J Cardiol 64 [Suppl. 11]:65F–69F
Henry PD, Bentley KI (1981) Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest 68:1366–1369
Henry PD (1990) Calcium antagonists as anti-atherosclerotic agents. Arteriosclerosis 10:963–965
Tedgui A, Chiron B, Curmi P, Juan L (1987) Effect of nicardipine and varapamil on in vitro albumin transport in rabbit thoracic aorta. Arteriosclerosis 7: 80–87
Habib JB, Bossaler C, Wells S, Williams C, Morrisett JD, Henry PD (1986) Preservation of endothelium-dependent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium blocker PN 200110. Cire Res 58:305–309
Moore JB, Fuller BL, Falotico R, Toman EL (1985) Inhibition of rabbit platelet phosphodiesterase activity and aggregation by calcium channel blockers. Thromb Res 40:401–411
Daugherty A, Rateri DL, Schonfeld G, Sobel BE (1987) Inhibition of choleteryl ester deposition in macrophages by calcium entry blockers : an effect dissociable from calcium entry blockade. Br J Pharmacol 91:113–118
Schmitz G, Robenek H et al. (1988) Ca++ antagonists and AC AT inhibitors promote cholesterol efflux from macrophages by different mechanisms. Arteriosclerosis 8:46–56
Etingin OR, Hajjar DP (1985) Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbit arterial smooth muscle cells. J Clin Invest 75:1554–1558
Nomoto A, Hirosumi J, Sekiguchi C, Mutoh S, Yamaguchi I, Aoki H (1987) Antiatherogenic activity of FR34235 (Nilvadipine) a new potent calcium antagonist. Atherosclerosis 64:255–261
Nilsson J, Sjolund M, Palmberg L, Von Euler AM, Jonzon B, Thyberg J (1985) The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation. Atherosclerosis 58:109–122
Weinstein DB, Heider JG (1987) Antiatherogenic properties of calcium antagonists. Am J Cardiol 59:163B–172B
Fleckenstein A (1983) Calcium antagonism in heart and smooth muscle. Wiley, New York, pp. 272–279
Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW (1990) Retardation of angiographic progression of coronary disease by nifedipine. Lancet 335:1109–1113
Loaldi A, Polese A, Montorsi P, De Cesare N, Fabbiocchi F, Ravagnani P, Guazzi MD (1989) Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris. Am J Cardiol 64:433–439
Gottlieb SO, Brinker JA, Mellits D, Achuff SC, Baughman KL, Traill TA, Weiss JL, Reitz BA, Weisfeldt ML, Gerstenblith G (1989) Effect of nifedipine on the development of coronary bypass graft stenoses in high-risk patients: a randomized, double-blind, placebo-controlled trial [abstract]. Circulation 80 [Suppl. H]: 11–228
Waters D, Lespérance J, Francetich M, Causey D, Théroux P, Chiang Y-K, Hudon G, Lemarbre L, Reitman M, Joyal M, Gosselin G, Dyrda I, Macer J, Havel RJ (1990) A controlled trial to assess the effect of a calcium channel blocker upon the progression of coronary atherosclerosis. Circulation 82: 1940–1953
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Henry, P.D. (1991). Nifedipine: A Pleiotropic Vascular Drug. In: Lichtlen, P.R., Reale, A. (eds) Adalat. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-85498-9_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-85498-9_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-85500-9
Online ISBN: 978-3-642-85498-9
eBook Packages: Springer Book Archive